Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000583589 | SCV000689338 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-04-25 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000701934 | SCV000830758 | uncertain significance | Familial cancer of breast; Fanconi anemia complementation group J | 2022-10-02 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 17 of the BRIP1 gene. It does not directly change the encoded amino acid sequence of the BRIP1 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRIP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 491442). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in activation of a cryptic splice site and introduces a premature termination codon (Invitae). The resulting mRNA is expected to undergo nonsense-mediated decay. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000583589 | SCV005547729 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-09-17 | criteria provided, single submitter | clinical testing | The c.2492+3A>C intronic variant results from an A to C substitution 3 nucleotides after coding exon 16 in the BRIP1 gene. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the available evidence, the clinical significance of this variant remains unclear. |